Increasing Access to Care: An Advanced Virtual Care Delivery Protocol to Deliver Diagnostic and Therapeutic Services to Underserved Veterans With ADRD
试验速览
- 阶段
- 不适用
- 状态
- 招募中
- 入组人数
- 30
- 试验地点
- 1
- 主要终点
- Time to Eligibility Determination
研究概览
简要总结
This study evaluates a care delivery protocol to improve access to care for Veterans with Alzheimer's Disease and Related Disorders (ADRD). A randomized controlled trial will enroll Veterans with mild cognitive impairment or early dementia at VA Pittsburgh. The ADRD care delivery protocol integrates telehealth, advanced diagnostics, and streamlined workflows to expedite screening for eligibility for amyloid targeting therapies.
研究设计
- 研究类型
- Interventional
- 分配方式
- Randomized
- 干预模型
- Single Group
- 主要目的
- Health Services Research
- 盲法
- None
入排标准
- 年龄范围
- 18 Years 至 —（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Diagnosis of mild cognitive impairment or mild dementia due to suspected or confirmed AD with a 5 minute telephone MoCA score >7
- •Meets VA MUE inclusion/
排除标准
- •for mAb therapy for AD
- •Enrolled in VA care
- •Lives in a home setting (i.e., not in an institutional setting such as a nursing home, Community Living Center, or hospital)
- •Has a working telephone
- •18 years and older
- •Able to communicate in English
- •Willing to give informed consent.
- •Exclusion Criteria:
研究组 & 干预措施
Usual Care
Patients will undergo usual care with all evaluation and testing at the discretion of the specialist.
ADRD Care Delivery Protocol
Patients will undergo telehealth preparedness assessment, cognitive screening, and blood biomarker testing prior to the initial consultation with the specialist.
干预措施: ADRD Care Delivery Protocol (Other)
结局指标
主要结局
Time to Eligibility Determination
时间窗: From date of randomization until the date of determination of eligibility for monoclonal antibody therapy, assessed up to 12 months.
Compare the number of days from randomization to the determination of eligibility for monoclonal antibody therapy for both the intervention and usual care groups, assessed up to 12 months.
Time to Initial Infusion
时间窗: From date of randomization until the date of first infusion, assessed up to 12 months.
Compare the number of days from the date of randomization to the initial infusion of monoclonal antibody therapy for both the intervention and usual care groups, assessed up to 12 months.
次要结局
- Number of Participants and Instances of Additional testing(1 year)